Consistent with these treatment-induced reductions in PBMC and plasma pro-inflammatory genes and factors, respectively, bromocriptine-QR therapy also reduced the plasma CRP level by 45%, an indicator of low-grade systemic inflammation and a potential predictor of CVD, especially in T2D patients [151,152,153]. The gene discussed is CRP; the disease is type 2 diabetes mellitus.